Citation

Saraf G, Behere RV, Venkatasubramanian G, Rao NP, Varambally S, Gangadhar BN. Am. J. Ther. 2014; 21(3): e80-e81.

Copyright

(Copyright © 2014, Lippincott Williams and Wilkins)

DOI

10.1097/MJT.0b013e3182456de7

PMID

unavailable

Abstract

Aripiprazole, due to its partial agonist activity at the D2 receptors, is often recommended as the drug of choice in patients who develop antipsychotic-induced hyperprolactinemia. We report a case of a female patient who developed hyperprolactinemia while on treatment with aripiprazole. This partial D2 agonistic activity of aripiprazole could be dose related, and hence, at higher doses, aripiprazole by itself can have dopamine antagonistic properties and hence cause prolactin system abnormalities. © 2013 Lippincott Williams & Wilkins.

Language: en

Keywords

Humans; adolescent; Female; adult; human; Adolescent; female; case report; bipolar disorder; depression; suicide attempt; lithium; Dopamine Agonists; Dose-Response Relationship, Drug; article; neuroleptic agent; prolactin; prolactin blood level; psychologic assessment; priority journal; quetiapine; sleep disorder; psychopharmacotherapy; follow up; extrapyramidal symptom; risperidone; weight gain; drug withdrawal; hyperprolactinemia; valproic acid; mania; outpatient care; dose response; menstrual cycle; metabolism; Antipsychotic Agents; dopamine 2 receptor; aripiprazole; body mass; euphoria; dopamine receptor blocking agent; Piperazines; Quinolones; dopamine receptor stimulating agent; Dopamine Antagonists; chemically induced; piperazine derivative; quinolone derivative; young adult; oligomenorrhea; psychomotor activity; Hyperprolactinemia; hand tremor; drug effects; cog wheel phenomenon; D2 receptor; Receptors, Dopamine D2